NewAmsterdam Pharma Stock (NASDAQ:NAMS)
Previous Close
$29.33
52W Range
$17.63 - $42.20
50D Avg
$33.29
200D Avg
$33.14
Market Cap
$3.54B
Avg Vol (3M)
$1.21M
Beta
0.08
Div Yield
-
NAMS Company Profile
NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, represents a pioneering and targeted inhibitor that acts on the Cholesteryl Ester Transfer Protein (CETP). This compound has demonstrated in clinical studies its capacity to lower low-density lipoprotein cholesterol (LDL-C) and, concurrently, significantly elevate high-density lipoprotein cholesterol (HDL-C). Established in 2019, the company is headquartered in Naarden, the Netherlands.
NAMS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| VKTX | Viking Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| CGON | CG Oncology, Inc. Common stock |
| LGND | Ligand Pharmaceuticals Incorporated |
| AKRO | Akero Therapeutics, Inc. |
| IMVT | Immunovant, Inc. |